We asked our freelance writers to share their top ideas for stocks listed on the Alternative Investment Market (AIM) with ...

It has been a little over a year since my article highlighting five speculative Aim shares for 2021 ... or small cap stocks, in the six months after news of the vaccines broke in early November ...

Looking ahead to 2024, the company is planning its largest-ever exploration program that could potentially serve as a bullish catalyst for the stock. One of the best-performing gold producers.

This AIM stock is backed by a profitable, growing business but it’s also making decent advances in the North American market. When investing, your capital is at risk. The value of your ...

When Aim reached its 20th anniversary in 2015, most investors were not reaching for the Champagne. Nearly three quarters of firms listed on the London Stock Exchange’s market for growth ...

The right online broker can help you execute your investment strategy and make trading cheap stocks seamless. Take a look at some of Benzinga’s favorites. You have found stocks to buy now cheap ...

Controller vs keyboard and mouse is one of the never-ending battles in the world of gaming, with diehard proponents on both sides of the fence. [Tech Yesterday] has been working to create a ...

Owning stocks is a great way to potentially increase your wealth over time. The S&P 500 stock market index, for example, generated an annualized total return of 10.5% between its inception in 1957 ...

There are some growth stocks in my portfolio that I consider indispensable. While I recognise circumstances can always change, my aim is to hold on to these two shares indefinitely. The first ...

Pros and Cons of Mutual Funds Mutual funds have several advantages over individual stock picking. Beyond diversifying your holdings, some mutual funds aim to outperform the stock market ...

The stock has more than doubled in 2024 but is still trading under $5. Investors are growing increasingly optimistic that imetelstat could gain additional approvals. Geron is in phase 3 clinical ...